{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:08:29Z","timestamp":1778904509097,"version":"3.51.4"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Clear cell carcinoma (CCC) of the endometrium is an uncommon yet aggressive tumor. Few cohort studies are reporting the overall survival time of CCC patients. This study aimed to retrospectively analyze the clinicopathologic features, molecular characteristics and survival data of 27 endometrial CCC patients to improve the understanding of CCC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The clinicopathologic features, molecular characteristics and survival data total of 27 CCC patients admitted to the BBMU affiliated hospital (Anhui, China) between January 2005 and December 2018 were retrospectively analyzed. Kaplan-Meier method was used to analyze the prognosis-related factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median age of the patients was 60 years (range; 39 to 81 years). The average tumor size was 3.8 cm (range; 0.8 to 13.0cm). Myometrial infiltration greater than 50% was reported in 55.6% of the patients, while the Ki-67 index greater than 50% was reported in 70.4% of the patients. The patients\u2019 FIGO (2009) surgical stages were as follows: 18 I, 3 II, 4 III, and 2 IV. Besides, 7 (25.6%) patients had lymphovascular invasion, 3 (11.1%) patients with distant metastasis, including 1 patient with bone metastasis, and 2 with liver metastasis. Adjuvant treatment included 7 with chemotherapy alone, 9 with radiotherapy alone, and 9 with both radiotherapy and chemotherapy. The median overall survival time from the time of CCC diagnosis was 56 months. ER and PR showed negative expression and P16 showed patchy immunostaining. 18 (63%) cases showed Napsin A positive expression. Loss of MSH2, MSH6 and PTEN were seen in 5, 4 and 7 cases respectively. All cases showed HER-2\/nue negative expression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CCC is a rare and invasive tumor. Age of diagnosis, FIGO stage, tumor size, myometrial infiltration, lymphovascular invasion, distant metastasis, Ki-67 index and P53 expression are important indicators to evaluate patient\u2019s prognosis (P = 0.048, P &amp;lt; 0.001, P = 0.016, P = 0.043, P = 0.001, P &amp;lt; 0.001, P = 0.026, and P = 0.007, respectively). CCC\u00a0has a worse prognosis than endometrioid carcinoma (P = 0.002), and there is no significant difference when compared with uterine papillary serous carcinoma (P = 0.155).<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.732782","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T08:49:21Z","timestamp":1638434961000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Clear Cell Carcinoma of the Endometrium: Evaluation of Prognostic Parameters in 27 Cases"],"prefix":"10.3389","volume":"11","author":[{"given":"Zhiyang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penglian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengqi","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linggong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damin","family":"Chai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"B1","article-title":"Clear Cell Carcinoma of the Endometrium: A Biological and Clinical Enigma","volume":"30","author":"Gadducci","year":"2010","journal-title":"Anticancer Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.10.025","article-title":"Translational Genomics of Ovarian Clear Cell Carcinoma","volume":"61","author":"Khalique","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.08.017","article-title":"Challenges for Immunotherapy for the Treatment of Platinum Resistant Ovarian Cancer","author":"Le Saux","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2019.06.005","article-title":"Clear Cell Carcinoma of the Endometrium: An Immunohistochemical and Molecular Analysis of 45 Cases","volume":"92","author":"Zannoni","year":"2019","journal-title":"Hum Pathol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1006\/gyno.2000.5737","article-title":"The Outcome of Stage I\u2013II Clinically and Surgically Staged Papillary Serous and Clear Cell Endometrial Cancers When Compared With Endometrioid Carcinoma","volume":"77","author":"Cirisano","year":"2000","journal-title":"Gynecol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-015-3973-x","article-title":"Adjuvant Therapy of Uterine Clear Cell Carcinoma: A Review","volume":"293","author":"Xu","year":"2016","journal-title":"Arch Gynecol Obstet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0000000000000430","article-title":"Morphologic and Immunohistochemical Study of Clear Cell Carcinoma of the Uterine Endometrium and Cervix in Comparison to Ovarian Clear Cell Carcinoma","volume":"37","author":"Ju","year":"2018","journal-title":"Int J Gynecol Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.5.1474","article-title":"Estrogen Receptor Status by Immunohistochemistry is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer","volume":"17","author":"Harvey","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/PGP.0000000000000111","article-title":"Should Endometrial Clear Cell Carcinoma be Classified as Type II Endometrial Carcinoma","volume":"34","author":"Bae","year":"2015","journal-title":"Int J Gynecol Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0000000000000491","article-title":"High-Grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations","author":"Murali","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.12789","article-title":"A Proposal for Updating the Staging of Endometrial Cancer","volume":"145","author":"Maheshwari","year":"2019","journal-title":"Int J Gynaecol Obstet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800057","article-title":"Molecular Characterization of Uterine Clear Cell Carcinoma","volume":"17","author":"An","year":"2004","journal-title":"Mod Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two Pathogenetic Types of Endometrial Carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100487","article-title":"When Should We Order a Next Generation Sequencing Test in a Patient With Cancer","volume":"25","author":"Colomer","year":"2020","journal-title":"EClinicalMedicine"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.07.013","article-title":"Microbes in Gynecologic Cancers: Causes or Consequences and Therapeutic Potential","author":"Wahid","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.semcancer.2019.09.021","article-title":"Repurposing Quinacrine for Treatment-Refractory Cancer","volume":"68","author":"Oien","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2006.09.035","article-title":"Accuracy of Preoperative Endometrial Sampling for the Detection of High-Grade Endometrial Tumors","volume":"196","author":"Huang","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1159\/000327864","article-title":"Pap Smears in Women With Endometrial Carcinoma","volume":"45","author":"Gu","year":"2001","journal-title":"Acta Cytol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.5114\/pm.2016.61186","article-title":"An Update of the Classical Bokhman\u2019s Dualistic Model of Endometrial Cancer","volume":"15","author":"Wilczynski","year":"2016","journal-title":"Prz Menopauzalny"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2016-0570","article-title":"The Role of Pathology in the Management of Patients With Endometrial Carcinoma","volume":"13","author":"Bartosch","year":"2017","journal-title":"Future Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2006.00494.x","article-title":"Clear Cell Adenocarcinoma of the Endometrium Is a Biologically Distinct Entity From Endometrioid Adenocarcinoma","volume":"16","author":"Arai","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/1066896917731862","article-title":"Endometrial Serous Carcinoma With Clear-Cell Change: Frequency and Immunohistochemical Analysis","volume":"26","author":"Hariri","year":"2018","journal-title":"Int J Surg Pathol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000350","article-title":"Infrequent Immunohistochemical Expression of Napsin A in Endometrial Carcinomas","volume":"25","author":"Al-Maghrabi","year":"2017","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/s0046-8177(98)80002-6","article-title":"Clear Cell Carcinoma of the Endometrium is Characterized by a Distinctive Profile of P53, Ki-67, Estrogen, and Progesterone Receptor Expression","volume":"29","author":"Lax","year":"1998","journal-title":"Hum Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1487-3","article-title":"PIpelle Prospective ENDOmetrial Carcinoma (PIPENDO) Study, Pre-Operative Recognition of High Risk Endometrial Carcinoma: A Multicentre Prospective Cohort Study","volume":"15","author":"Visser","year":"2015","journal-title":"BMC Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s0029-7844(02)02391-8","article-title":"Chambers J. E-Cadherin Expression in Endometrioid, Papillary Serous, and Clear Cell Carcinoma of the Endometrium","volume":"100","author":"Holcomb","year":"2002","journal-title":"Obstet Gynecol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000085","article-title":"Frequent Expression of Napsin A in Clear Cell Carcinoma of the Endometrium: Potential Diagnostic Utility","volume":"38","author":"Fadare","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated Genomic Characterization of Endometrial Carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30745","article-title":"Somatic Mutation Profiles of Clear Cell Endometrial Tumors Revealed by Whole Exome and Targeted Gene Sequencing","volume":"123","author":"Le Gallo","year":"2017","journal-title":"Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/path.4947","article-title":"The Genetic Landscape of Endometrial Clear Cell Carcinomas","volume":"243","author":"DeLair","year":"2017","journal-title":"J Pathol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001209","article-title":"Targeted Molecular and Immunohistochemical Analyses of Endometrial Clear Cell Carcinoma Show That POLE Mutations and DNA Mismatch Repair Protein Deficiencies Are Uncommon","volume":"43","author":"Baniak","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2020.04.043","article-title":"Molecular Subtypes of Clear Cell Carcinoma of the Endometrium: Opportunities for Prognostic and Predictive Stratification","volume":"158","author":"Kim","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/his.12581","article-title":"Targeted Mutation Analysis of Endometrial Clear Cell Carcinoma","volume":"66","author":"Hoang","year":"2015","journal-title":"Histopathology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(09)62002-x","article-title":"Survival Effect of Para-Aortic Lymphadenectomy in Endometrial Cancer (SEPAL Study): A Retrospective Cohort Analysis","volume":"375","author":"Todo","year":"2010","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh316","article-title":"Phase III Randomized Trial of Doxorubicin + Cisplatin Versus Doxorubicin + 24-H Paclitaxel + Filgrastim in Endometrial Carcinoma: A Gynecologic Oncology Group Study","volume":"15","author":"Fleming","year":"2004","journal-title":"Ann Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.07.184","article-title":"Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study","volume":"22","author":"Fleming","year":"2004","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.02.003","article-title":"2nd. Management of Women With Clear Cell Endometrial Cancer: A Society of Gynecologic Oncology (SGO) Review","volume":"113","author":"Olawaiye","year":"2009","journal-title":"Gynecol Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000001050","article-title":"Clear Cell Carcinoma of the Endometrium: Evaluation of Prognostic Parameters in a Multi-Institutional Cohort of 165 Cases","volume":"27","author":"Abdulfatah","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ygyno.2018.12.007","article-title":"National Patterns of Care and Cancer-Specific Outcomes of Adjuvant Treatment in Patients With Serous and Clear Cell Endometrial Carcinoma","volume":"152","author":"Xiang","year":"2019","journal-title":"Gynecol Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000643","article-title":"Role of Adjuvant Therapy for Stage IA Serous and Clear Cell Uterine Cancer: Is Observation a Valid Strategy","volume":"26","author":"Velker","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.17.00146","article-title":"Adjuvant Carboplatin and Paclitaxel Chemotherapy Followed by Radiotherapy in High-Risk Endometrial Cancer: A Retrospective Analysis","volume":"4","author":"Rodrigues da Cunha Colombo Bonadio","year":"2018","journal-title":"J\u00a0Glob Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01575","article-title":"Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel\/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer","volume":"37","author":"Randall","year":"2019","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30395-x","article-title":"Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): Patterns of Recurrence and Post-hoc Survival Anal Randomised Phase 3 Trial","volume":"20","author":"de Boer","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.732782\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T08:49:25Z","timestamp":1638434965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.732782\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":44,"alternative-id":["10.3389\/fonc.2021.732782"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.732782","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]},"article-number":"732782"}}